€25.38
5.93% yesterday
Amsterdam, Nov 22, 05:35 pm CET
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Galapagos Stock price

€25.38
-2.64 9.42% 1M
-0.76 2.91% 6M
-11.61 31.39% YTD
-8.83 25.81% 1Y
-19.03 42.84% 3Y
-144.12 85.03% 5Y
+12.48 96.74% 10Y
Amsterdam, Closing price Fri, Nov 22 2024
+1.42 5.93%
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Key metrics

Market capitalization €1.67b
Enterprise Value €-1.75b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 3.32
EV/Sales (TTM) EV/Sales -3.21
P/S ratio (TTM) P/S ratio 3.07
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth -5.75%
Revenue (TTM) Revenue €543.97m
EBIT (operating result TTM) EBIT €-208.88m
Free Cash Flow (TTM) Free Cash Flow €-525.95m
Cash position €3.38b
EPS (TTM) EPS €-2.33
P/E forward negative
P/S forward 5.71
EV/Sales forward negative
Show more

Is Galapagos a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Galapagos Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Galapagos forecast:

3x Buy
21%
10x Hold
71%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Galapagos forecast:

Buy
21%
Hold
71%
Sell
7%

Financial data from Galapagos

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
544 544
6% 6%
100%
- Direct Costs 39 39
32% 32%
7%
526 526
1% 1%
97%
- Selling and Administrative Expenses 269 269
35% 35%
49%
- Research and Development Expense 444 444
1% 1%
82%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -209 -209
22% 22%
-38%
Net Profit -153 -153
2,848% 2,848%
-28%

In millions EUR.

Don't miss a Thing! We will send you all news about Galapagos directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galapagos Stock News

Neutral
GlobeNewsWire
17 days ago
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024.
Neutral
Seeking Alpha
23 days ago
Galapagos NV (NASDAQ:GLPG ) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO & COO Jeevan Shetty - Head of Development Oncology Wulf Bocher - Head Immunology Therapeutic Area Conference Call Participants Xian Deng - UBS Judah Frommer - Morgan Stanley Alexander Kelly - TD Cow...
Neutral
GlobeNewsWire
24 days ago
Webcast presentation   on   October 31, 2024,   at 1 3 :00 CET   /   8:00 am ET,   www.glpg.com
More Galapagos News

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Head office Belgium
CEO Paulus Stoffels
Employees 1,123
Founded 1999
Website www.glpg.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today